SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer
Status:
Unknown status
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This is an exploratory, single-armed, open label study on the efficacy and safety of
sequential S-1 therapy after SOX in unresectable metastatic or locally advanced biliary
system or periampullary cancer or pancreatic cancer patients. The primary endpoint is
Objective response rate and secondary endpoint is progression free survival , overall
survival ,1 year survival rate and safety.